AP2014008084A0 - Compositions comprising shortacting benzodiazepines - Google Patents

Compositions comprising shortacting benzodiazepines

Info

Publication number
AP2014008084A0
AP2014008084A0 AP2014008084A AP2014008084A AP2014008084A0 AP 2014008084 A0 AP2014008084 A0 AP 2014008084A0 AP 2014008084 A AP2014008084 A AP 2014008084A AP 2014008084 A AP2014008084 A AP 2014008084A AP 2014008084 A0 AP2014008084 A0 AP 2014008084A0
Authority
AP
ARIPO
Prior art keywords
shortacting
benzodiazepines
compositions
shortacting benzodiazepines
Prior art date
Application number
AP2014008084A
Other languages
English (en)
Inventor
Alan James Baillie
John Aitken Graham
Kevin Richard Ward
Original Assignee
Paion Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48669863&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2014008084(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Paion Uk Ltd filed Critical Paion Uk Ltd
Publication of AP2014008084A0 publication Critical patent/AP2014008084A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AP2014008084A 2012-05-22 2013-05-22 Compositions comprising shortacting benzodiazepines AP2014008084A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12168968 2012-05-22
PCT/EP2013/060543 WO2013174883A1 (fr) 2012-05-22 2013-05-22 Compositions comprenant des benzodiazépines à action rapide

Publications (1)

Publication Number Publication Date
AP2014008084A0 true AP2014008084A0 (en) 2014-11-30

Family

ID=48669863

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2014008084A AP2014008084A0 (en) 2012-05-22 2013-05-22 Compositions comprising shortacting benzodiazepines

Country Status (42)

Country Link
US (2) US20150148338A1 (fr)
EP (1) EP2852389B1 (fr)
JP (1) JP6313286B2 (fr)
KR (1) KR102116737B1 (fr)
CN (2) CN104968348B (fr)
AP (1) AP2014008084A0 (fr)
AR (1) AR092008A1 (fr)
AU (1) AU2013265295B2 (fr)
BR (1) BR112014029108B1 (fr)
CA (1) CA2874247C (fr)
CL (1) CL2014003171A1 (fr)
CO (1) CO7151503A2 (fr)
DK (1) DK2852389T3 (fr)
EA (1) EA032119B1 (fr)
EC (1) ECSP14032553A (fr)
ES (1) ES2651389T3 (fr)
FR (1) FR21C1043I2 (fr)
GE (1) GEP20186852B (fr)
HK (1) HK1208164A1 (fr)
HR (1) HRP20171872T1 (fr)
HU (2) HUE037734T2 (fr)
IL (1) IL235789B (fr)
LT (2) LT2852389T (fr)
LU (1) LUC00230I2 (fr)
MA (1) MA37581B1 (fr)
MX (1) MX368854B (fr)
MY (1) MY185117A (fr)
NL (1) NL301130I2 (fr)
NO (2) NO2852389T3 (fr)
NZ (1) NZ702063A (fr)
PE (1) PE20150683A1 (fr)
PH (1) PH12014502608A1 (fr)
PL (1) PL2852389T4 (fr)
PT (1) PT2852389T (fr)
RS (1) RS56660B1 (fr)
SG (1) SG11201407710VA (fr)
SI (1) SI2852389T1 (fr)
TN (1) TN2014000479A1 (fr)
TW (1) TWI590826B (fr)
UA (1) UA115063C2 (fr)
WO (1) WO2013174883A1 (fr)
ZA (1) ZA201408412B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0714886B8 (pt) 2006-07-10 2021-05-25 Paion Uk Ltd sais de benzodiazepina, seus usos e seus processos de preparação, e composição farmacêutica
EP2305647A1 (fr) 2009-09-18 2011-04-06 PAION UK Limited Procédé de préparation d'ester de méthyle d'acide 3-[(4S)-8-bromo-1-méthyl-6-(2-pyridinyl)-4H-imidazo[1,2-a][1,4]benzodiazépine-4-yl] propionique ou son sulfonate de benzène, et composants utiles dans ce procédé
EP2450039A1 (fr) 2010-11-08 2012-05-09 PAION UK Ltd. Régime de dosage permettant la sédation avec CNS 7056 (Remimazolam)
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
WO2015076340A1 (fr) * 2013-11-21 2015-05-28 小野薬品工業株式会社 Composition injectable pour l'anesthésie générale et/ou la sédation
ES2958606T3 (es) 2014-02-10 2024-02-12 Biolumic Ltd Mejoras en y relacionadas con el control de características de organismos fotosintéticos
CN111615947B (zh) 2014-03-14 2021-08-17 拜欧卢米克有限公司 提高作物产量和/或质量的方法
WO2016011943A1 (fr) * 2014-07-23 2016-01-28 李勤耕 Nouveau dérivé de benzodiazépine et son utilisation
JP2017529076A (ja) 2014-09-17 2017-10-05 バイオルミック リミテッド 種子処理の方法およびその結果として得られる生産物
CN105726495B (zh) * 2014-12-12 2019-03-29 宜昌人福药业有限责任公司 一种注射用短效苯并二氮杂卓盐药物组合物及其制备方法
CN107198691A (zh) * 2016-03-17 2017-09-26 江苏恒瑞医药股份有限公司 一种瑞马唑仑的药物组合物
EP3442539A1 (fr) * 2016-04-14 2019-02-20 Paion UK Limited Benzodiazépines à usage nasal et inhalées par voie orale
CN108289897B (zh) * 2016-05-20 2020-07-28 江苏恒瑞医药股份有限公司 一种瑞马唑仑的药物组合物
EP3500082A1 (fr) 2016-08-22 2019-06-26 Biolumic Limited Système, dispositif et méthodes de traitement de semences
CN108503644B (zh) 2016-12-09 2019-06-14 成都倍特药业有限公司 一种苯并二氮杂*衍生物的氢溴酸盐及其制备方法和用途
EP3714884A1 (fr) 2019-03-27 2020-09-30 Paion UK Limited Utilisations médicales pour benzodiazépines dotées d'un motif eeg particulier
CN112209932B (zh) * 2019-07-12 2023-03-24 成都倍特药业股份有限公司 一种化合物氢溴酸盐的新固体形态及其制备方法和用途
ES2803099B2 (es) * 2019-07-22 2021-11-08 Moehs Iberica Sl Procedimiento de obtención de besilato de remimazolam amorfo
CN114478535B (zh) * 2020-10-23 2024-02-09 成都苑东生物制药股份有限公司 一种苯磺酸瑞马唑仑ii晶型的制备方法
CN112462015B (zh) * 2020-11-18 2022-07-12 海南倍特药业有限公司 一种氢溴酸瑞马唑仑细菌内毒素的检测方法
CN114624351B (zh) * 2020-12-14 2024-04-09 宜昌人福药业有限责任公司 苯磺酸瑞马唑仑原料药中(r)-(-)-1-氨基-2-丙醇残留的分析方法
WO2024126745A1 (fr) * 2022-12-16 2024-06-20 Lts Lohmann Therapie-Systeme Ag Système d'administration par voie oromucosale contenant du remimazolam

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3520877A (en) * 1967-10-02 1970-07-21 Hoffmann La Roche 3-carbonyl amino acetic acid ethyl ester substituted benzodiazepines
CA2143246C (fr) 1994-03-16 2000-08-22 Thierry Godel Imidazodiazepines
ATE203026T1 (de) 1995-01-06 2001-07-15 Hoffmann La Roche Hydroxymethyl-imidazodiazepine und deren ester
AU4382896A (en) 1995-02-02 1996-08-21 F. Hoffmann-La Roche Ag Acetylimidazobenzodiazepines
JPH0971533A (ja) * 1995-06-30 1997-03-18 Takeda Chem Ind Ltd 凍結乾燥製剤
US7160880B1 (en) * 1999-05-14 2007-01-09 Cenes Limited Short-acting benzodiazepines
GB9911152D0 (en) * 1999-05-14 1999-07-14 Glaxo Group Ltd Short-acting benzodiazepines
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
EP1161949A1 (fr) * 2000-06-09 2001-12-12 Warner-Lambert Company Utilisation de diazepino-indoles dans le traitement des bronchopneumopathies chroniques obstructive
EP2353590A1 (fr) * 2005-02-15 2011-08-10 Elan Pharma International Limited Aérosol et composition injéctable de benzodiazépine nanoparticulaire
GB0613693D0 (en) * 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts (3)
GB0613692D0 (en) * 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts
BRPI0714886B8 (pt) * 2006-07-10 2021-05-25 Paion Uk Ltd sais de benzodiazepina, seus usos e seus processos de preparação, e composição farmacêutica
CN101352422B (zh) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 河豚毒素冻干粉针制剂及其制备方法
CN102781943B (zh) * 2009-11-05 2016-10-05 葛兰素史密丝克莱恩有限责任公司 苯并二氮杂*溴结构域抑制剂
EP2450039A1 (fr) * 2010-11-08 2012-05-09 PAION UK Ltd. Régime de dosage permettant la sédation avec CNS 7056 (Remimazolam)
CN102964349A (zh) 2011-08-31 2013-03-13 江苏恒瑞医药股份有限公司 苯并二氮杂*衍生物的托西酸盐及其多晶型、它们的制备方法和用途

Also Published As

Publication number Publication date
GEP20186852B (en) 2018-05-25
LTPA2021521I1 (fr) 2021-10-11
PT2852389T (pt) 2017-12-13
TW201400119A (zh) 2014-01-01
JP2015517552A (ja) 2015-06-22
JP6313286B2 (ja) 2018-04-18
US20150148338A1 (en) 2015-05-28
NZ702063A (en) 2016-11-25
PL2852389T4 (pl) 2022-02-21
SG11201407710VA (en) 2015-01-29
ECSP14032553A (es) 2018-11-30
EA032119B1 (ru) 2019-04-30
EA201492160A1 (ru) 2015-10-30
CN108578413A (zh) 2018-09-28
CO7151503A2 (es) 2014-12-29
CL2014003171A1 (es) 2015-06-19
FR21C1043I2 (fr) 2022-10-07
AU2013265295A1 (en) 2015-01-22
MY185117A (en) 2021-04-30
DK2852389T3 (en) 2017-12-18
RS56660B1 (sr) 2018-03-30
BR112014029108A2 (pt) 2017-06-27
PH12014502608B1 (en) 2015-01-21
NO2021041I1 (no) 2021-09-20
KR102116737B1 (ko) 2020-05-29
HRP20171872T1 (hr) 2018-02-23
CA2874247C (fr) 2020-07-28
MA37581B1 (fr) 2016-07-29
HK1208164A1 (en) 2016-02-26
UA115063C2 (uk) 2017-09-11
WO2013174883A1 (fr) 2013-11-28
ES2651389T3 (es) 2018-01-26
LUC00230I2 (fr) 2022-10-07
MX368854B (es) 2019-10-18
NO2852389T3 (fr) 2018-03-17
LT2852389T (lt) 2017-12-27
EP2852389A1 (fr) 2015-04-01
BR112014029108B1 (pt) 2022-02-08
HUS2100040I1 (hu) 2021-10-28
CN104968348B (zh) 2018-04-17
HUE037734T2 (hu) 2018-09-28
NL301130I2 (nl) 2021-10-25
IL235789A0 (en) 2015-01-29
MA20150233A1 (fr) 2015-07-31
AU2013265295B2 (en) 2017-08-31
MX2014014225A (es) 2015-06-17
CN104968348A (zh) 2015-10-07
PL2852389T3 (pl) 2018-02-28
IL235789B (en) 2019-07-31
TN2014000479A1 (en) 2016-03-30
FR21C1043I1 (fr) 2021-11-19
PE20150683A1 (es) 2015-06-03
PH12014502608A1 (en) 2015-01-21
ZA201408412B (en) 2016-09-28
NL301130I1 (fr) 2021-09-22
TWI590826B (zh) 2017-07-11
EP2852389B1 (fr) 2017-10-18
AR092008A1 (es) 2015-03-18
CA2874247A1 (fr) 2013-11-28
US20220040198A1 (en) 2022-02-10
SI2852389T1 (en) 2018-02-28
KR20150009601A (ko) 2015-01-26

Similar Documents

Publication Publication Date Title
HUS2100040I1 (hu) Rövid ideig ható benzodiazepineket tartalmazó készítmények
HK1215165A1 (zh) 組合物
HK1210019A1 (en) Chitosan-derived compositions
HK1208354A1 (en) Compositions
GB201210800D0 (en) Compositions
GB201209244D0 (en) Compositions
GB201201287D0 (en) Compositions
ZA201503062B (en) Compositions
GB201220068D0 (en) Compositions
ZA201502542B (en) Compositions
GB201219973D0 (en) Compositions
GB201219980D0 (en) Compositions
GB201219962D0 (en) Compositions
TWI561248B (en) Peracid-generating compositions
EP2926813A4 (fr) Compositions de métformine-orlistat
GB201223148D0 (en) Compositions
GB201222702D0 (en) Compositions
GB201218959D0 (en) Compositions
GB201209187D0 (en) Compositions
GB201209189D0 (en) Compositions
GB201204102D0 (en) Compositions
GB201204103D0 (en) Compositions
GB201203082D0 (en) Compositions
GB201203083D0 (en) Compositions
GB201203084D0 (en) Compositions